Chr amplification(11)(q13)

News alerts, weekly reports and conference planners

Chr amplification(11)(q13)	Nasopharyngeal Carcinoma	Chr amplification(11)(q13)	Nasopharyngeal Carcinoma	toripalimab-tpzi Resistant: C3 – Early Trials toripalimab-tpzi Resistant : C3	toripalimab-tpzi Resistant: C3 – Early Trials toripalimab-tpzi Resistant : C3
Chr amplification(11)(q13)	Gastric Adenocarcinoma	Chr amplification(11)(q13)	Gastric Adenocarcinoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
Chr amplification(11)(q13)	Hepatocellular Cancer	Chr amplification(11)(q13)	Hepatocellular Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
Chr amplification(11)(q13)	Hepatocellular Cancer	Chr amplification(11)(q13)	Hepatocellular Cancer	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3

Associations